Economic burden of recurrent hyperkalemia in patients with chronic kidney disease
Recurrent hyperkalemia in patients with stage 3/4 CKD was associated with higher all-cause HRU and medical costs compared with normokalemia (including in patients with Medicare coverage and RAASi use) and nonrecurrent hyperkalemia. Research is needed to understand if long-term treatment strategies aimed at preventing hyperkalemia recurrence may alleviate this economic burden.
Authors
- Abiy Agiro (ORCID: https://orcid.org/0000-0002-2369-8507)
- George L. Bakris (ORCID: https://orcid.org/0000-0003-1183-1267)
- Elaine Louden (ORCID: https://orcid.org/0000-0003-1231-2223)
- Erin Cook (ORCID: https://orcid.org/0000-0001-9737-9130)
- Manasvi Sundar (ORCID: https://orcid.org/0000-0001-5858-8685)
- Alexandra Greatsinger (ORCID: https://orcid.org/0000-0001-8576-8614)
- Fan Mu (ORCID: https://orcid.org/0000-0003-0252-0387)
- Ellen Colman
- Pooja Desai (ORCID: https://orcid.org/0000-0002-9546-0901)
Institutions
- Hypertension Institute (US)
- AstraZeneca (United States) (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2024-08-05
- DOI
- https://doi.org/10.18553/jmcp.2024.24114
- Citations
- 1
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.42